Auric Goldfinger's Short List Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sir Auric Goldfinger who wrote (4660)	1/24/2000 9:28:00 PM
From: RockyBalboa	Read Replies (1) of 19428

XOMA soared to $9 after news that baxter buys the worldwide Neuprex right for $35MM in aggregate... XOMA itself is valued at $500MM ($9/shr)....isn't that sort of a stiff premium? $35MM is not even $1/shr (55.6MM out) biz.yahoo.com Baxter and XOMA Enter Agreement for Neuprex in Meningococcemia and Related Future Indications DEERFIELD, Ill. and BERKELEY, Calif., Jan. 24 /PRNewswire/ -- Baxter Healthcare Corporation and XOMA Ltd. (Nasdaq: XOMA - news) announced today an agreement in which Baxter's Hyland Immuno division has acquired the worldwide rights to XOMA's NEUPREX® (rBPI21) for treatment of meningococcemia and all future anti-bacterial and anti-endotoxin indications. Meningococcemia is a deadly systemic bacterial infection caused by a species of bacteria that can also cause meningitis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next